Peli BioThermal opens first network station in China

Pharma packaging provider Peli BioThermal has opened its first network station in China. 

Located in Shanghai, the station will serve worldwide customers of the Crēdo on Demand rental programme.

Dominic Hyde, vice president global services at Peli BioThermal, said: “China is the second largest pharmaceutical market in the world, and the country has plans to significantly grow its pharmaceutical industry over the next five years.

“Our new network station will make temperature controlled shipping logistics more convenient for customers doing work in the broader Asia-Pacific region.”

The Shanghai market is home to several of China’s top 10 pharmaceutical manufacturers including Shanghai Pharmaceuticals and Shanghai Fosun Pharmaceutical, and is a base for major pharma companies including Johnson & Johnson, Roche, Novartis, Pfizer, Bayer, AstraZeneca and GlaxoSmithKline.

Peli BioThermal, the life science industry’s cold chain partner, stated that China is a growing component in the global market for the manufacturing and distribution of pharmaceuticals, including as the leading producer of active pharmaceutical ingredients and a key producer of generic drugs.

Through the Made in China 2025 plan, China aims to further grow its pharmaceutical industry, focusing on drug innovation through research and development.

According to the International Trade Administration, China’s pharmaceutical market value reached almost $134bn in 2018 and is expected to grow to $161.8bn by 2023.

Shanghai joins Peli BioThermal’s network of more than 100 network stations and drop points around the world and is the fourth network station in the Asia-Pacific region.

Peli BioThermal relocates US HQ to increase production capabilities

Seko Logistics and Peli BioThermal partner for pharma operations in Ireland